LCT extends cash runway with receipt from Vertex acquisition
Filed with ASX · · 2 pages · English
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- LCT to benefit from Semma Therapeutics acquisition by Vertex
- Preliminary Final Report and 2019 Financial Statements
- NTCELL Parkinsons trial patient data 2 years after implant
- NTCELL Parkinsons trial patient data at 18 months
- Preliminary Final Report and 2018 Financial Statements
Later from Algorae Pharmaceuticals
- Appendix 4C - quarterly
- Response to ASX Aware Query
- Amended Appendix 4C
- Preliminary Final Report and 2020 Financial Statements
- LCT CEO Dr Ken Taylor signals intention to retire
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals